The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Abstract
The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of rapamycin (mTOR) represent two vital intracellular signaling pathways, which are associated with various aspects of cellular functions. These functions play vital roles in quiescence, survival, and growth in normal physiological circumstances as well as in various pathological disorders, including cancer. These two pathways are so intimately connected to each other that in some instances these are considered as one unique pathway crucial for cell cycle regulation. The purpose of this review is to emphasize the role of PI3K-Akt-mTOR signaling pathway in different cancer conditions and the importance of natural products targeting the PI3K-Akt-mTOR signaling pathway. This review also aims to draw the attention of scientists and researchers to the assorted beneficial effects of the numerous classes of natural products for the development of new and safe drugs for possible cancer therapy. We also summarize and critically analyze various preclinical and clinical studies on bioactive compounds and constituents, which are derived from natural products, to target the PI3K-Akt-mTOR signaling pathway for cancer prevention and intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–212 of 212
Rapamycin inhibits tumor growth of human osteosarcomas.
Zhao, S., Lu, N.-J., Chai, Y., & Yu, X. (2015) · PubMed · Cited by 25
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
Modak, S. I., & Sun, . (2012) · OncoTargets and Therapy · doi:10.2147/ott.s14578 · Cited by 24
Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?
Gao, Y., Yuan, C. Y., & Yuan, W. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.07.02 · Cited by 24
Yang, W., Schwartz, G. N., Marotti, J. D., Chen, V., Traphagen, N. A., Gui, J., & Miller, T. W. (2018) · Oncotarget · doi:10.18632/oncotarget.24256 · Cited by 23
Al‐Batran, S., Riera‐Knorrenschild, J., Pauligk, C., Goetze, T. O., Hegewisch‐Becker, S., Seraphin, J., Thuss-Patience, P. C., Kopp, H., Dechow, T. N., Vogel, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.4 · Cited by 22
Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
Arteaga, C. L. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_54 · Cited by 19
Allgäuer, A., Schreiner, E., Ferrazzi, F., Ekici, A. B., Gerbitz, A., Mackensen, A., & Völkl, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501389 · Cited by 19
Towards Targeted Therapy of Chronic Lymphocytic Leukemia
Niemann, C. U., Jones, J. E., & Wiestner, A. U. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8051-8_12 · Cited by 18
Yoon, H., & Park, C. M. (2019) · Biomolecules · doi:10.3390/biom9070288 · Cited by 18
Chen, Y., Tang, Y., Tang, Y., Yang, Z., & Ding, G. (2019) · Marine Drugs · doi:10.3390/md17060366 · Cited by 14
Liu, B., Xu, L., Dai, E., Tian, J., & Li, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181501 · Cited by 13
Qian, Y., Yang, T., Zhao, X., Yan, Y., Li, W., Fang, C., Hou, J., Li, T., & Liu, Y. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2397-0 · Cited by 10
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets
Zhang, M., Liu, Q., Meng, H., Duan, H., Liu, X., Wu, J., Gao, F., Wang, S., Tan, R., & Yuan, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01688-x · Cited by 712
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07326 · Cited by 301
Metadata
- Authors
- Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 80
- Pages
- 1-17
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2995204555
- Cited by
- 642
- References
- 212
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.